THE MOST IMPORTANT ORGANIC COMPOUNDS USED IN BREAKING UP KIDNEY STONES
Abstract
In this research, we talked about the most important organic compounds used in breaking up kidney stones, what are their types and causes, and the benefit of each compound or treatment.
It discusses the most important treatments used to break up kidney stones, such as cystone, U_Urayl, and other treatments. It deals with organic compounds, their composition, and nomenclature according to the IUPAC system.
References
1. Klee et al 1991, GRASESF et al 1990, krambeck et al 2006, Finkielstein et al 2006
2. IH Zahid, AS Bawazir, and R. Naser, “Plant based native T herapy for the treatment of Kidney stones in Aurangabad (MS),” Journal of Pharmacognosy and Phytochemistry, vol. 1, N o. 6, pp. 189–193, 2013.
3. N. Chhiber, M. Sharma, T. Kaur, and S. Singla, “Minerali- Zation in health and mechanism of kidney stone formation,” International Journal of Pharmaceutical Science Invention, V ol. 3, pp. 25–31, 2014.
4. C. Barbasa, A. Garciaa, L. Saavedraa, and M. Muros, “Urinary A analysis of nephrolithiasis markers,” Journal of Chroma- T ography B, vol. 781, no. 1-2, pp. 433–455, 2002.
5. F. L. Coe, A. Evan, and E. Worcester, “Kidney stone disease,” Journal of Clinical Investigation, vol. 115, no. 10, pp. 2598–2608, 2005.
6. A. Chaudhary, S. K. Singla, and C. Tandon, “In vitro eval- Uation of Terminalia arjuna on calcium phosphate and C alcium oxalate crystallization,” Indian Journal of Pharma- C eutical Sciences, vol. 72, no. 3, pp. 340–345, 2010.
7. F. L. Coe, J. H. Parks, and J. R. Asplin, “e pathogenesis and treatment of kidney stones,” New England Journal of Med - Icine, vol. 327, no. 16, pp. 1141–1152, 1992.
8. A. Skolarikos, M. Straub, T. Knoll et al., “Metabolic evaluation and recurrence prevention for urinary stone patients: EAU guidelines,” ropean Urology, vol. 67, no. 4,pp. 750–763, 2015.
9. A. Bensatal and MR Ouahrani, “Inhibition of crystallization of calcium oxalate by the extraction of Tamarix gallica L,”Urological Research, vol. 36, no. 6, pp. 283–287, 2008.
10. DR Basavaraj, CS Biyani, AJ Browning, and JJ Cartledge, “e role of urinary kidney stone inhibitors and promoters in the pathogenesis of calcium containing renal stones,” EAU-EBU Update Series, vol. 5, no. 3, pp. 126–136, 2007.
11. F. Dal-Moro, M. Mancini, I. M. Tavolini, V. De Marco, and P. Bassi, “Cellular and molecular gateways to urolithiasis: a new insight,” Urologia Internationalis, vol. 74, pp. 193–197,
12. D. V. Kishore, F. Moosavi, and D. R. K. Varma, “Effect of Ethanolic extract of Portulaca oleracea linn. on ethylene glycol and ammonium chloride induced urolithiasis,” In-international Journal of Pharmacy and Pharmaceutical Sci- ences, vol. 5, no. 2, pp. 134–140, 2013.
13. Kidney Stone Causes, Symptoms, Treatments.
14. Zarse, CA, et al. 2004. Helical computed tomography - P hy accurately reports urinary stone composition U sing attenuation values: in vitro verification using H high-resolution micro-computed tomography cali- B rated to fourier transform infrared microspec- T roscopy. Urology. 63:828–833.
15. Lingeman, JE, Kim, SC, Kuo, RL, McAteer, JA, A nd Evan, AP 2003. Shockwave lithotripsy: anecdotes and insights. J. Endourol. 17:687–693.
16. Bagley, D. H. 2002. Expanding the role of ureteroscopy and laser lithotripsy for the treatment of proximal U reteral and intrarenal calculi. Curr. Opin. Urol. 12:277–280.
17. Clayman, R. V. 2005. Percutaneous nephrolithotomy: an update [comment]. J. Urol. 173:1199.
18. Gillen, DL, Worcester, EM, and Coe, FL 2005.Decreased renal function among adults with a history of nephrolithiasis: a study of NHANES III.Kidney Int. 67:685–690.
19. Madore, F., Stampfer, M.J., Rimm, E.B., and Curhan, G.C. 1998. Nephrolithiasis and risk of hypertension . Am. J. Hypertens. 11:46–53.
20. Brown, CM, and Purich, DL 1992. Physical-Chemical processes in kidney stone formation. In disorders of bone and mineral metabolism. FL Coe and MJ Favus, editors. Raven Press. New York, NewYork, USA. 613–624.
21. Parks, J. H., Coward, M., and Coe, F. L. 1997. Cor- R espondence between stone composition and urine S upersaturation in nephrolithiasis. Kidney Int.51:894–900.
22. Parks, JH, Goldfischer, ER, and Coe, FL 2003. Changes in urine volume accomplished by physi- cians treating nephrolithiasis. J. Urol. 169:863–866.
23. https://images.app.goo.gl/QcKM2ZUbdZh8KDn28
24. https://images.app.goo.gl/oFxc5QEwJS7sdeQx8 Rodman JS, Reckler JM, Israel AR. Hemiacidrin irrigations to D solve stone remnants after nephrolithotomy. Problems with solution flow. Urology 1981;18:127–130.
25. Erickson, S. B., Vrtiska, T. J., & Lieske, J. C. (2011). Effect of Cystone® on urinary composition and stone formation over a one year period. Phytomedicine: international journal of phytotherapy and phytopharmacology, 18(10), 863–867.
26. Effect of Cystone® on Urinary Composition and Stone Formation Over a One Year Period. Retrieved on the 17th of November 202 .
27. Brunton, L.L., Knollmann, B.C., & Hilal-Dandan, R.G. (2018). Gilman's the pharmacological basis of therapeutics. New York City
28. DiPiro , JT, Talbert, RL, Yee, GC, Matzke, GR, Wells, BG, & Posey, LM (2017). Pharmacotherapy: A Pathophysiologic Approach, 10 izdanje. Bernardo NO, Smith AD. Chemolysis of urinary calculi. Urol Clin North Am 2000;27:355–365.
29. Moffat AC, Osselton MD, Widdop B, Walts J. Clarke's Analysis of Drugs and Poisons. 14th ed. London: Pharmaceutical Press; 2011. p. 1788.
30. Oʼneil MJ, Heckelman PE, Dobbelaar PH, Roman KJ. The Merck Index. 15th ed. USA: The Royal Society of Chemistry; 2013. p. 6686.
31. Munoz-Davila MJ. Role of old antibiotics in the era of antibiotics resistance. Highlighted nitrofurantoin for the treatment of lower urinary tract infections. Antibiotics 2014;3:39-48.
32. Yang L, Wang K, Li H, Denstedt JD, Cadieux PA. The influence of urinary pH on antibiotic efficacy against bacterial uropathogens.Urology 2014;84:731.e1-7.
33. Imming P, Sinning C, Meyer A. Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov 2006;5:821-34.
34. King Draw
35. Goodman, L.S., Gilman, G.A., Gilman, A. ( 1980 ) The Pharmacological Basis of Therapeutics, 6th ed. , pp. 585 – 7
36. Blaivas JG, Pais VM, Spellman RM. Chemolysis of residual S tone fragments after extensive surgery for staghorn calculi. Urology 1975;6:680–686.
37. Crowell A. Cystine nephrolithiasis. Surg Gynecol Obstet 1924;38:87–91.
38. Schon MP, Boehncke WH, Brocker EB: Psoriasis: clinical manifestations, pathogenesis and therapeutic perspectives. Discov Med 2005;5:253-258.
39. A. Skolarikos, M. Straub, T. Knoll et al., “Metabolic evaluation and recurrence prevention for urinary stone patients:EAU guidelines,” European Urology, vol. 67, no. 4 , pp. 750–763, 2015.
